^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Tice BCG (live attenuated bacillus Calmette-Guerin)

i
Associations
Company:
Merck (MSD), Texas A&M University
Drug class:
Immunostimulant
Related drugs:
Associations
Phase 1
Northwestern University
Completed
Last update posted :
06/26/2024
Initiation :
02/10/2017
Primary completion :
05/15/2020
Completion :
08/05/2022
PD-L1 • PD-1 • PD-L2
|
Keytruda (pembrolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
Phase 3
UNICANCER
Active, not recruiting
Last update posted :
12/06/2023
Initiation :
01/17/2019
Primary completion :
04/01/2024
Completion :
02/01/2028
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
Phase 2/3
Carman Giacomantonio
Withdrawn
Last update posted :
02/14/2023
Initiation :
12/01/2021
Primary completion :
09/01/2022
Completion :
09/01/2022
IL2
|
Proleukin (aldesleukin) • Tice BCG (live attenuated bacillus Calmette-Guerin)
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
10/12/2022
Initiation :
10/28/2003
Primary completion :
01/03/2006
Completion :
09/30/2013
CTAG1B • CD4 • CTAG2
|
Leukine (sargramostim) • Tice BCG (live attenuated bacillus Calmette-Guerin)